US Drug Launch Prices Higher Than Ever in 2022

A Reuters analysis has found that US launch prices for new drugs are approaching record highs. The study found this year’s median annual price of 13 drugs recently approved by the Food and Drug Administration (FDA) for chronic conditions is $257,000, with seven other drugs reaching the $200,000+ range. The report comes as the Democrat’s signature Inflation Reduction Act is signed into law, which would let Medicare negotiate the prices of a small number of expensive drugs.

According to Reuters, “Last year, the median annual price rose to $180,000 for the 30 drugs first marketed through mid-July 2021, according to a study published recently in JAMA. While the Reuters tally does not completely replicate the work of that study, it shows that the direction of new drug prices continues to be on the rise.”

To read more, click here.

(Source: Reuters, August 16th, 2022)